Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets
Benjamin A. Weinberg, Joanne Xiu, Michael Lindberg, et al.
Journal of Gastrointestinal Oncology (2019) Vol. 10, Iss. 4, pp. 652-662
Open Access | Times Cited: 152

Showing 1-25 of 152 citing articles:

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, et al.
The Lancet (2023) Vol. 401, Iss. 10391, pp. 1853-1865
Open Access | Times Cited: 504
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancers (2021) Vol. 13, Iss. 3, pp. 558-558
Open Access | Times Cited: 234
Gallbladder cancer
Juan Carlos Roa, Patricia García, Vinay K. Kapoor, et al.
Nature Reviews Disease Primers (2022) Vol. 8, Iss. 1
Closed Access | Times Cited: 200
Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review
Audra Boscoe, Catherine Rolland, Robin Kate Kelley
Journal of Gastrointestinal Oncology (2019) Vol. 10, Iss. 4, pp. 751-765
Open Access | Times Cited: 162
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Sumera I. Ilyas, Silvia Affò, Lipika Goyal, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 7, pp. 470-486
Open Access | Times Cited: 93
Immunology and immunotherapy of cholangiocarcinoma
Tim F. Greten, Robert F. Schwabe, Nabeel Bardeesy, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 6, pp. 349-365
Closed Access | Times Cited: 92
SERS sensing for cancer biomarker: Approaches and directions
Lorena Vázquez‐Iglesias, Giovanna Casagrande, Daniel García‐Lojo, et al.
Bioactive Materials (2023) Vol. 34, pp. 248-268
Open Access | Times Cited: 65
Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches
Divya Khosla, Shagun Misra, Pek Lim Chu, et al.
Cancers (2024) Vol. 16, Iss. 4, pp. 801-801
Open Access | Times Cited: 18
Overview of current targeted therapy in gallbladder cancer
Xiaoling Song, Yunping Hu, Yongsheng Li, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 132
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
Changhoon Yoo, Do-Youn Oh, Hye Jin Choi, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000564-e000564
Open Access | Times Cited: 126
Recent advances of immunotherapy for biliary tract cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Review of Gastroenterology & Hepatology (2020) Vol. 15, Iss. 5, pp. 527-536
Closed Access | Times Cited: 116
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 4, pp. 343-350
Closed Access | Times Cited: 101
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial
Shalini Makawita, Ghassan K. Abou‐Alfa, Sameek Roychowdhury, et al.
Future Oncology (2020) Vol. 16, Iss. 30, pp. 2375-2384
Closed Access | Times Cited: 83
First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!”
Alessandro Rizzo, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100335-100335
Open Access | Times Cited: 83
Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer
Alessandro Rizzo, Giovanni Brandi
Expert Review of Gastroenterology & Hepatology (2021) Vol. 15, Iss. 5, pp. 547-554
Closed Access | Times Cited: 79
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100337-100337
Open Access | Times Cited: 77
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures
Kabir Mody, Prerna Jain, Sherif El-Refai, et al.
JCO Precision Oncology (2022), Iss. 6
Open Access | Times Cited: 45
Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions
Niklas Sturm, Jasmin Schuhbaur, Felix J. Hüttner, et al.
Cancers (2022) Vol. 14, Iss. 22, pp. 5580-5580
Open Access | Times Cited: 39
Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies
Justin H. Lo, Rajiv Agarwal, Laura W. Goff, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3312-3312
Open Access | Times Cited: 27
Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies
Samantha M. Ruff, Timothy M. Pawlik
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 12
Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis
Giorgio Frega, Fernando P. Cossío, Jesús M. Bañales, et al.
Cells (2023) Vol. 12, Iss. 16, pp. 2098-2098
Open Access | Times Cited: 21
Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts’ position paper
Matteo Fassan, Valentina Angerilli, Nicola Normanno, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 194, pp. 104224-104224
Open Access | Times Cited: 8
Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma)
Christopher Jakubowski, Nilofer S. Azad
Chinese Clinical Oncology (2020) Vol. 9, Iss. 1, pp. 2-2
Open Access | Times Cited: 46
Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine
Ines Malenica, Matteo Donadon, Ana Lleò
Cancers (2020) Vol. 12, Iss. 8, pp. 2190-2190
Open Access | Times Cited: 44
Page 1 - Next Page

Scroll to top